SCHEMBL19781807

SCHEMBL19781807

CC(C)Oc1ccc(-c2cnc3ccc(-c4ccc(OC(C)C)cc4F)cn23)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 2/20 0.43
DYRK1A Q13627 1/20 0.43
PIK3CA P42336 2/20 0.42
MTOR P42345 2/20 0.42
CYP1A2 P05177 1/20 0.40
FLT3 P36888 3/20 0.40
KCNH2 Q12809 1/20 0.38
TGFBR1 P36897 3/20 0.38
FYN P06241 1/20 0.37
ALOX5AP P20292 4/20 0.37
FEN1 P39748 4/20 0.37
FFAR4 Q5NUL3 1/20 0.37
RIPK2 O43353 1/20 0.36
BCL2 P10415 1/20 0.36
MDM2 Q00987 1/20 0.36
MCL1 Q07820 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19781804 0.87 SCN5A (0.42) CLK1DYRK1APIK3CAMTORCYP1A2
SCHEMBL24460240 0.84 PIK3CA (0.44) CLK1DYRK1APIK3CAMTORCYP1A2
SCHEMBL19781539 0.84 CLK1 (0.47) CLK1DYRK1APIK3CAMTORCYP1A2
SCHEMBL19781775 0.83 FLT3 (0.51) CLK1DYRK1APIK3CAMTORCYP1A2
SCHEMBL19781558 0.83 PIK3CA (0.46) CLK1DYRK1APIK3CAMTORCYP1A2
SCHEMBL24460186 0.82 PIK3CA (0.50) CLK1DYRK1APIK3CAMTORCYP1A2
SCHEMBL19781553 0.81 SCN5A (0.50) CLK1DYRK1APIK3CAMTORCYP1A2
SCHEMBL19781168 0.81 SCN5A (0.50) CLK1DYRK1APIK3CAMTORCYP1A2
SCHEMBL24460237 0.81 PIK3CA (0.48) CLK1DYRK1APIK3CAMTORCYP1A2
SCHEMBL26362205 0.80 PIK3CA (0.55) CLK1DYRK1APIK3CAMTORCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2023-09-28 US disclosed
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2023-09-28 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
WO-2022108849-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2022-05-27 WO disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
WO-2018013430-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS C3AR1, C9, C1R CLK1 3537/4885DYRK1A 4426/4885PIK3CA 1740/4885
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S CLK1 3012/4885DYRK1A 4561/4885PIK3CA 4298/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S CLK1 3012/4885DYRK1A 4561/4885PIK3CA 4298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.